Squamous Cell Carcinoma
Advertisement
Researchers presented results from the randomized controlled trial of mPATH-Lung at the CHEST Annual Meeting.
Annette McWilliams, MBBS, FRACP, PhD, discusses her IASLC Presidential Symposium presentation on the study.
Eric Singhi, MD, discusses the key milestone that will be celebrated at the conference, which will be held in San Diego.
Learn how clinicians can take practical steps to ensure patients with lung cancer receive comprehensive biomarker testing.
Recent data show that less than half of patients are receiving biomarker testing results before starting treatment.
The EC approval is primarily based on the results from GEMSTONE-302, a multicenter, randomized, double-blind phase 3 study.
The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities.
Following observational studies that suggested an association between psoriasis and lung cancer risk, researchers ...
An article in Thoracic Cancer reported that dual high expression of T cell immunoreceptor with immunoglobulin and ITIM ...
Patients with autoimmune diseases—including rheumatoid arthritis (RA)—do not have poorer lung cancer survival ...
The novel agent tislelizumab improved progression-free survival (PFS; primary endpoint) in the firstline setting in ...
The U.S. Food and Drug Administration approved pembrolizumab in combination with carboplatin and either paclitaxel or ...
Researchers at NYU School of Medicine have recently developed an artificial intelligence (AI) system that is capable of ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.